Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1010.049 - 1033.205 Dr. Andrea Apolo

So patients with variant histology often are not included in trials. So I do love the fact that they did include patients with variant histology in this study. And I treat these patients as I would regular urothelial carcinoma, unless there's a small cell component in it or a neuroendocrine, a high-grade neuroendocrine component. Then I treat them as more like a lung component.